Visioneering Technologies Releases One-Year Data From Myopia Progression Control Study

Visioneering Technologies (ASX:VTI) said that full one-year results of its Progressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial showed that 45% of subjects in the test

MT NewswiresJan 18 19:14 ET

Visioneering Technologies Issues Part of Shortfall From Rights Offering

Visioneering Technologies (ASX:VTI) issued 1,084,843 CHESS depositary interests, forming part of the shortfall from its recent nonrenounceable rights offering. The shortfall securities were issued at

MT NewswiresJan 4 20:33 ET

Visioneering Technologies Raising Funds for Clinical Trial, Business Expansion

Visioneering Technologies (ASX:VTI) is looking to raise up to $2.6 million in funding from a rights offering and share placement, according to a Tuesday filing. The medical device company is targeting

MT NewswiresOct 10, 2023 07:08 ET

Visioneering Technologies Appoints CEO

Visioneering Technologies (ASX:VTI) appointed Juan Carlos Aragón as its chief executive officer and executive director, effective Oct. 1, the US-based medical device company said Tuesday. Aragón has

MT NewswiresAug 28, 2023 20:02 ET